Quantity of eligible individuals: CDEC mentioned the uncertainty in the volume of patients with reasonably serious to critical hemophilia B in Canada suitable for etranacogene dezaparvovec. Scientific specialists consulted by CADTH indicated that some patients who are classified as getting mild or average disease may have a severe bleeding phenotype, https://cashnsttt.mybloglicious.com/55975286/hemgenix-an-overview